Abbott Receives FDA and CE Mark for AI-Enabled Imaging Device
Abbott has received 510(k) clearance and a CE mark for its AI-powered Ultreon 3.0 coronary imaging platform. The device, announced last week, combines optical coherence tomography (OCT) with artificial intelligence to assist doctors in assessing plaque blocking blood vessels and in the selection and placement of stents.
Details
Ultreon 3.0 enhances the previous version by introducing features that improve image clarity, speed, and clinical insight. OCT uses infrared light to generate high-resolution images of the vessel wall, playing an essential role in evaluating the need for lesion preparation and choosing the appropriate stent size.
Company Background
Abbott, a global healthcare company, has a portfolio of vascular technologies that saw a 9.5% sales growth in the first quarter. The company is committed to developing innovative medical devices that leverage the latest in imaging and AI technology.
Market Context
This AI-enabled imaging device is significant as it represents a step forward in the precision and efficiency of coronary imaging. The integration of AI into OCT technology is a testament to the ongoing innovation in medical device engineering, aiming to enhance patient outcomes and procedural accuracy.
If you are exploring product design and medical device engineering, BangDesign has relevant experience.
Source: MedTech Dive